Market Place
Sourcing Support
NewAmsterdam Pharma Reports Q3 Financials & Corporate Update
06 Nov 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Inducement Grants Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Join Medical and Investor Conferences
28 Oct 2024 //
#N/A
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Rule
04 Oct 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
30 Aug 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Q2 Results And Provides Corporate Update
07 Aug 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule
02 Aug 2024 //
GLOBENEWSWIRE
NewAmsterdam Reports Positive Phase 3 Data For Obicetrapib In FH Patients
29 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam`s Cholesterol Drug Underperforms In Phase 3 Test
29 Jul 2024 //
FIERCE BIOTECH
NewAmsterdam To Announce Phase 3 BROOKLYN Trial Data For Obicetrapib July 29
26 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Appoints Two New Board Members
18 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam Completes Enrollment For Obicetrapib-Ezetimibe Combo TANDEM Trial
08 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule
03 Jul 2024 //
GLOBENEWSWIRE
NewAmsterdam Announces Issuance of Composition of Matter Patent for Obicetrapib
11 Jun 2024 //
GLOBENEWSWIRE
NewAmsterdam Reports Inducement Grants Per Nasdaq
07 Jun 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
29 May 2024 //
GLOBENEWSWIRE
NewAmsterdam To Present Obicetrapib Cardio Risk Data
21 May 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Q1 2024 Update And Financials
09 May 2024 //
GLOBENEWSWIRE
NewAmsterdam Reports Nasdaq Listing Rule Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
02 May 2024 //
GLOBENEWSWIRE
NewAmsterdam Enrolls 9,000+ patients in Trial
09 Apr 2024 //
GLOBENEWSWIRE
NewAmsterdam shares more data on lipid-lowering Amgen castoff
08 Apr 2024 //
FIERCE PHARMA
NewAmsterdam Announces the Appointment of Juliette as Chief Business Officer
01 Apr 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2
25 Mar 2024 //
GLOBENEWSWIRE
NewAmsterdam #Doses First Patient in Phase 3 Evaluating Obicetrapib & Ezetimibe
12 Mar 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
26 Feb 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares
13 Feb 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering
13 Feb 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Present at 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Appoints William H. Lewis as Chair of its Board of Directors
08 Jan 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Announces 2024 Strategic Priorities
04 Jan 2024 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Third Quarter 2023 Financial Highlights
13 Nov 2023 //
GLOBENEWSWIRE
NewAmsterdam Announces Appointment of Ian Somaiya as Chief Financial Officer
23 Oct 2023 //
GLOBENEWSWIRE
NewAmsterdam Announces Initial Data from Phase 2a Trial Evaluating Obicetrapib
21 Sep 2023 //
GLOBENEWSWIRE
NewAmsterdam to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Second Quarter 2023 Financial Highlights
07 Aug 2023 //
GLOBENEWSWIRE
NewAmsterdam Completes Enrollment in Phase 3 Trial Evaluating Obicetrapib
25 Jul 2023 //
GLOBENEWSWIRE
Could obicetrapib facilitate sufficient LDL-cholesterol levels?
28 Jun 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
NewAmsterdam Announces Commencement of Secondary Offering of Ordinary Shares
06 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Announces Pricing of Upsized Secondary Offering of Ordinary Shares
06 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Announces Results from Phase 2b Trial Evaluating Obicetrapib
05 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib
03 Jun 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
23 May 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter
08 May 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Completes Enrollment in Pivotal Ph3
24 Apr 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
03 Apr 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Reports Full Year 2022 Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
06 Feb 2023 //
GLOBENEWSWIRE
NewAmsterdam notches another win in resurrection of Amgen cardio drug
18 Jan 2023 //
ENDPTS
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
19 Dec 2022 //
GLOBENEWSWIRE
NewAmsterdam Debuts as Publicly Traded Company Focused on Developing Obicetrapib
23 Nov 2022 //
GLOBENEWSWIRE
NewAmsterdam takes SPAC route to fund phase 3 trials
23 Nov 2022 //
FIERCEBIOTECH
Frazier Acquisition Corp Shareholders Approve Combination with NewAmsterdam
15 Nov 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study
05 Oct 2022 //
BUSINESSWIRE
NewAmsterdam Shows Leadership in Cardiometabolic Disease Treatment at Congress
29 Aug 2022 //
BUSINESSWIRE
NewAmsterdam Pharma Announces Publication in Nature Medicine
11 Aug 2022 //
BUSINESSWIRE
